NO314458B1 - Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon - Google Patents
Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon Download PDFInfo
- Publication number
- NO314458B1 NO314458B1 NO19911164A NO911164A NO314458B1 NO 314458 B1 NO314458 B1 NO 314458B1 NO 19911164 A NO19911164 A NO 19911164A NO 911164 A NO911164 A NO 911164A NO 314458 B1 NO314458 B1 NO 314458B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- antigen
- gene
- construct
- mhc
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 210000004962 mammalian cell Anatomy 0.000 title claims description 17
- 238000010276 construction Methods 0.000 title claims description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 97
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 230000003902 lesion Effects 0.000 claims description 19
- 230000009466 transformation Effects 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000002779 inactivation Effects 0.000 claims description 12
- 230000010354 integration Effects 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000013507 mapping Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 abstract description 11
- 238000002744 homologous recombination Methods 0.000 abstract description 11
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract description 7
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 33
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 25
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- -1 (3-actin Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
- Lubricants (AREA)
- Special Wing (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38565189A | 1989-07-25 | 1989-07-25 | |
| US43187289A | 1989-11-06 | 1989-11-06 | |
| PCT/US1990/004178 WO1991001140A1 (en) | 1989-07-25 | 1990-07-25 | Homologous recombination for universal donor cells and chimeric mammalian hosts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO911164L NO911164L (no) | 1991-03-22 |
| NO911164D0 NO911164D0 (no) | 1991-03-22 |
| NO314458B1 true NO314458B1 (no) | 2003-03-24 |
Family
ID=27011096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19911164A NO314458B1 (no) | 1989-07-25 | 1991-03-22 | Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5416260A (ja) |
| EP (2) | EP0950707B1 (ja) |
| JP (1) | JPH04501510A (ja) |
| KR (1) | KR100226158B1 (ja) |
| AT (1) | ATE423195T1 (ja) |
| AU (1) | AU633958B2 (ja) |
| DE (2) | DE69033493D1 (ja) |
| NO (1) | NO314458B1 (ja) |
| WO (1) | WO1991001140A1 (ja) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705732A (en) * | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US6689610B1 (en) * | 1989-08-22 | 2004-02-10 | University Of Utah Research Foundation | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
| US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5489742A (en) * | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
| AU9076191A (en) * | 1990-11-21 | 1992-06-25 | Massachusetts Institute Of Technology | Mice having beta 2 microglobulin gene disruption |
| WO1992021763A1 (en) * | 1991-05-31 | 1992-12-10 | Genentech, Inc. | Enhancement of expression by gene targeting in endogenous retrovirus-like sequences |
| WO1993002188A1 (en) * | 1991-07-15 | 1993-02-04 | Oklahoma Medical Research Foundation | Universal donor cells |
| WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2237747T3 (es) * | 1991-11-14 | 2005-08-01 | Prionics Ag | Animales transgenicos no humanos que carecen de proteinas prionicas. |
| US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
| US6916654B1 (en) * | 1992-06-29 | 2005-07-12 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
| JP3741447B2 (ja) * | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | エンドセリン−１遺伝子の機能が欠損したマウス |
| WO1994016080A1 (en) * | 1993-01-08 | 1994-07-21 | Exemplar Corporation | An in vitro/in vivo method for identifying anti-neoplastic drugs |
| US5610007A (en) * | 1993-01-21 | 1997-03-11 | Universite Laval | Chimeric sheets of epithelial cells |
| GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
| US5650550A (en) * | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
| WO1996006165A1 (en) * | 1994-08-19 | 1996-02-29 | The General Hospital Corporation | Genetically engineered swine cells |
| CA2202549C (en) * | 1994-10-14 | 2003-08-05 | Tara Seshadri | Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene |
| US6884622B1 (en) | 1995-04-21 | 2005-04-26 | Abgenix, Inc | Method for preparing a mammalian cell deficient in HPRT |
| WO1996033266A1 (en) * | 1995-04-21 | 1996-10-24 | Cell Genesys, Inc. | Generation of large genomic dna deletions |
| EP0842266A4 (en) * | 1995-08-04 | 1999-07-21 | Gen Hospital Corp | TRANSGENIC PORK AND PORK CELLS HAVING HLA GENES OF MAN |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| GB9703550D0 (en) * | 1997-02-20 | 1997-04-09 | Ppl Therapeutics Scotland Ltd | Cell mediated transgenesis |
| US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| EP0975755B2 (en) | 1997-04-16 | 2011-08-03 | Millennium Pharmaceuticals, Inc. | Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor |
| US7316923B1 (en) | 1997-09-26 | 2008-01-08 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
| US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
| US6194633B1 (en) | 1998-01-26 | 2001-02-27 | University Of Iowa Research Foundation | Non-human animal having a functionally disrupted SLP-76 gene |
| ATE264911T1 (de) | 1998-02-02 | 2004-05-15 | Univ Johns Hopkins Med | Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen |
| AU3964799A (en) * | 1998-04-24 | 1999-11-16 | University Of Nebraska Board Of Regents | Compositions and methods for the characterization and transplantation of mammalian retinal stem cells |
| US6733991B1 (en) | 1998-05-08 | 2004-05-11 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses therefor |
| US6746852B1 (en) | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
| US7531715B1 (en) | 1999-01-13 | 2009-05-12 | Ppl Therapeutics (Scotland) | Double nuclear transfer method and results thereof |
| EP1151010B1 (en) * | 1999-02-05 | 2005-10-26 | Therapeutic Human Polyclonals, Inc. | Human polyclonal antibodies from transgenic nonhuman animals |
| DE60036788T2 (de) * | 1999-02-18 | 2008-07-24 | Denise L. Weston Faustman | Verfahren zur inhibierung der abstossung von transplantaten |
| US7485293B1 (en) | 1999-02-18 | 2009-02-03 | Faustman Denise L | Method for inhibiting transplant rejection |
| EP1179000A4 (en) | 1999-02-26 | 2005-10-12 | Millennium Pharm Inc | DECISION PROTEINS AND THEIR USE |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| JP5113314B2 (ja) | 2000-09-01 | 2013-01-09 | ザ センター フォー ブラッド リサーチ インク | 所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法 |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| IL155952A0 (en) | 2000-11-28 | 2003-12-23 | Wyeth Corp | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| MXPA03004637A (es) | 2000-11-28 | 2003-09-05 | Wyeth Corp | Analisis de expresion de acidos nucleicos y polipeptidos kiaa utiles en diagnostico y tratamiento de cancer de prostata. |
| EP1916303B1 (en) * | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| ES2522890T3 (es) | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Método para recolectar células troncales placentarias |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| EP2336299A1 (en) | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| ES2522526T3 (es) | 2001-02-14 | 2014-11-14 | Anthrogenesis Corporation | Placenta post-parto de mamíferos, su uso y células troncales placentarias de la misma |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| EP2294917A1 (en) | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| JP2004533226A (ja) | 2001-04-02 | 2004-11-04 | ワイス | Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用 |
| EP2277897A1 (en) | 2001-04-16 | 2011-01-26 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| KR100583331B1 (ko) * | 2001-05-11 | 2006-05-26 | 기린 비루 가부시키가이샤 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
| WO2003002746A2 (en) * | 2001-06-29 | 2003-01-09 | Novartis Ag | Perv screening method and use thereof |
| US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
| EP1525323B1 (en) | 2001-11-09 | 2015-01-21 | Dana-Farber Cancer Institute, Inc. | Pgc-1beta, a novel pgc-1 homologue and uses therefor |
| EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| US7153685B2 (en) | 2002-03-11 | 2006-12-26 | The Board Of Trustees Of The University Of Illinois | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US20040091936A1 (en) * | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
| EP1572950B1 (en) | 2002-06-17 | 2012-10-10 | Thrasos, Inc. | Single domain tdf-related compounds and analogs thereof |
| CN102220423A (zh) | 2002-08-20 | 2011-10-19 | 千年药品公司 | 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法 |
| US20040171147A1 (en) | 2002-11-26 | 2004-09-02 | Hariri Robert J. | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7799518B2 (en) | 2003-10-07 | 2010-09-21 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| US7951532B2 (en) | 2003-11-12 | 2011-05-31 | Children's Hospital Medical Center | Method of screening a midkine modulating agent |
| US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
| EP2789342A1 (en) | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| WO2006012304A2 (en) | 2004-06-25 | 2006-02-02 | The Salk Institute For Biological Studies | Increasing life span by modulation of smek |
| CA2584814A1 (en) * | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglobulin expression in non-human transgenic animals |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
| US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
| CA2604580A1 (en) | 2005-04-15 | 2006-10-26 | President And Fellows Of Harvard College | Methods for modulating bone formation and mineralization by modulating krc activity |
| JP2009507835A (ja) | 2005-09-09 | 2009-02-26 | ジョンズ ホプキンス ユニバーシティ | 抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性ｔ細胞およびｄｃの機能の操作 |
| CA2623106C (en) | 2005-09-19 | 2013-12-24 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
| CA2863125A1 (en) | 2005-09-20 | 2007-03-29 | Thrasos Innovation, Inc. | Tdf-related compounds and analogs thereof |
| WO2007047468A2 (en) | 2005-10-13 | 2007-04-26 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| KR20190104428A (ko) | 2005-12-29 | 2019-09-09 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
| JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| US7875453B2 (en) | 2006-06-14 | 2011-01-25 | Bioe Llc | Differentiation of multi-lineage progenitor cells to hepatocytes |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CA2661848C (en) | 2006-09-01 | 2015-02-03 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| US20080188573A1 (en) * | 2007-02-02 | 2008-08-07 | Alcon Research, Ltd. | Use of thy1-fp transgenic mouse for the identification of ophthalmic agents |
| MX349225B (es) | 2007-02-12 | 2017-07-19 | Anthrogenesis Corp | Uso de celulas madre placentarias para preparar medicamentos utiles en el tratamiento de padecimientos inflamatorios. |
| US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| KR20210022148A (ko) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
| US8663980B2 (en) | 2007-10-26 | 2014-03-04 | Janssen Biotech, Inc. | Vectors, host cells, and methods of production and uses |
| US8101354B2 (en) * | 2008-01-15 | 2012-01-24 | University Of Kentucky Research Foundation | Method for screening for a tobiano coat color genotype |
| EP3539380A3 (en) | 2008-08-20 | 2019-12-18 | Celularity, Inc. | Improved cell composition and methods of making the same |
| DK2367932T3 (da) | 2008-11-19 | 2019-09-23 | Celularity Inc | Amnion-afledte adhærente celler |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| EP2261242A1 (en) | 2009-06-10 | 2010-12-15 | Universite Catholique De Louvain | Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method |
| ES2559937T3 (es) | 2009-09-23 | 2016-02-16 | Davinci Biosciences Llc | Células madre de revestimiento del cordón umbilical y métodos y material para aislar y cultivar las mismas |
| US9745589B2 (en) | 2010-01-14 | 2017-08-29 | Cornell University | Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination |
| AU2011207210A1 (en) | 2010-01-22 | 2012-08-16 | Dana-Farber Cancer Institute, Inc. | Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
| ES2646750T3 (es) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias |
| TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
| HUE029144T2 (hu) | 2010-04-07 | 2017-02-28 | Anthrogenesis Corp | Angiogenezis méhlepény õssejtek használatával |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| EP2593542B1 (en) | 2010-07-13 | 2018-01-03 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
| WO2012109238A2 (en) | 2011-02-07 | 2012-08-16 | President And Fellows Of Harvard College | Methods for increasing immune responses using agents that directly bind to and activate ire-1 |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| EP3443968A1 (en) | 2011-06-01 | 2019-02-20 | Celularity, Inc. | Treatment of pain using placental stem cells |
| WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| MY164836A (en) | 2011-10-28 | 2018-01-30 | Regeneron Pharma | Genetically modified major histocompatibility complex mice |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| PT2770822T (pt) | 2011-10-28 | 2017-09-18 | Regeneron Pharma | Ratinhos geneticamente modificados que expressam moléculas quiméricas de complexo principal de histocompatibilidade (mhc) ii |
| PL2814842T3 (pl) | 2012-02-15 | 2018-12-31 | Novo Nordisk A/S | Przeciwciała wiążące białko 1 rozpoznające peptydoglikan |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP3196214B1 (en) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| CN105142651A (zh) | 2013-02-05 | 2015-12-09 | 人类起源公司 | 来自胎盘的自然杀伤细胞 |
| SI2958938T1 (sl) | 2013-02-20 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Miši, ki izražajo humanizirane koreceptorje za celice T |
| US10154658B2 (en) | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| ES2724300T3 (es) | 2013-09-25 | 2019-09-10 | Univ Cornell | Compuestos para inducir inmunidad antitumoral y métodos de lo mismo |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
| EP4248744A3 (en) | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| WO2017075329A2 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| US12006550B2 (en) | 2020-10-12 | 2024-06-11 | University Of South Carolina | Targeting treatment for ADAM30 in pathological cells |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK105582A (da) * | 1982-03-11 | 1983-09-12 | Nordisk Insulinlab | Fremgangsmaade til bestemmelse af humane hla-d(r) vaevstyper og gensonde til brug ved fremgangsmaaden |
-
1990
- 1990-07-25 EP EP99108460A patent/EP0950707B1/en not_active Expired - Lifetime
- 1990-07-25 AT AT99108460T patent/ATE423195T1/de not_active IP Right Cessation
- 1990-07-25 DE DE69033493T patent/DE69033493D1/de not_active Expired - Lifetime
- 1990-07-25 KR KR1019910700311A patent/KR100226158B1/ko not_active IP Right Cessation
- 1990-07-25 JP JP2511319A patent/JPH04501510A/ja active Pending
- 1990-07-25 AU AU61505/90A patent/AU633958B2/en not_active Ceased
- 1990-07-25 EP EP90911928A patent/EP0437576B1/en not_active Expired - Lifetime
- 1990-07-25 DE DE69034263T patent/DE69034263D1/de not_active Expired - Fee Related
- 1990-07-25 WO PCT/US1990/004178 patent/WO1991001140A1/en active IP Right Grant
- 1990-11-09 US US07/611,020 patent/US5416260A/en not_active Expired - Lifetime
-
1991
- 1991-03-22 NO NO19911164A patent/NO314458B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO911164L (no) | 1991-03-22 |
| EP0950707A1 (en) | 1999-10-20 |
| DE69034263D1 (de) | 2009-04-02 |
| US5416260A (en) | 1995-05-16 |
| JPH04501510A (ja) | 1992-03-19 |
| EP0950707B1 (en) | 2009-02-18 |
| AU633958B2 (en) | 1993-02-11 |
| KR920701419A (ko) | 1992-08-11 |
| ATE423195T1 (de) | 2009-03-15 |
| NO911164D0 (no) | 1991-03-22 |
| DE69033493D1 (de) | 2004-08-12 |
| AU6150590A (en) | 1991-02-22 |
| EP0437576B1 (en) | 2002-07-03 |
| WO1991001140A1 (en) | 1991-02-07 |
| EP0437576A1 (en) | 1991-07-24 |
| EP0437576A4 (en) | 1992-06-10 |
| KR100226158B1 (ko) | 1999-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314458B1 (no) | Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon | |
| US5413923A (en) | Homologous recombination for universal donor cells and chimeric mammalian hosts | |
| EP0626012B1 (en) | Homogenotization of gene-targeting events | |
| KR100233781B1 (ko) | 동종 재조합을 이용하는 단백질 제조방법 | |
| AU2011286185B2 (en) | Transgenic animals and methods of use | |
| US20050149998A1 (en) | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same | |
| KR19990007937A (ko) | 큰 게놈 ｄｎａ 결실 유발법 | |
| KR20190093171A (ko) | CRISPR/Cas9 시스템을 통한 닭 백혈병 바이러스(Avian Leukosis Virus, ALV) 저항성 조류의 제조방법 | |
| CA2385162A1 (en) | Compositions and methods for altering gene expression | |
| JP2005504552A (ja) | ターゲティングベクターの調製方法およびその使用 | |
| AU684275B2 (en) | Method for defined deletions of DNA | |
| JP2002520023A (ja) | インフルエンザウイルスｍ２タンパク質の条件突然変異体 | |
| KR101911515B1 (ko) | 단계별 면역거부반응 억제 다중유전자가 α-Ｇａｌ 유전자에 적중된 복합형질전환 세포주 및 그의 제조방법 | |
| US20230357715A1 (en) | Method for preparing effector cells with desired specificity | |
| CA2037907C (en) | Homologous recombination for universal donor cells and chimeric mammalian hosts | |
| JPH10509313A (ja) | トランスジェニック生物およびその使用方法 | |
| CN114854791A (zh) | 一种新型CRISPR-Cas9系统载体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |